a receptor tyrosine kinase of the highly-conserved FGFR family that binds fibroblast growth factor (FGF). Mutations are associated with thanatophoric dysplasia (TD), craniosynostosis Adelaide type, many craniosynostotic syndromes and bone malformations. Three splice-variant isoforms have been described. Activating point mutations cause dwarfism, including achondroplasia, hypochrondroplasia and thanatophoric dysplasia, and facial and other morphogenetic disorders, including Crouzon syndrome, craniosynostosis Adelaide type, San Diego skeletal displasia and Muenke syndrome. Translocations t(4;14) involving the IgH region are common in multiple myeloma and frequently involve FGFR3. Activated FGFR3 found in 30% of bladder cancers and several cervical cancers, but not in other tumors. Two mutations found in colorectal cancer. Note: This description may include information from UniProtKB.
Protein type: Kinase, protein; Protein kinase, TK; EC 126.96.36.199; Protein kinase, tyrosine (receptor); Membrane protein, integral; TK group; FGFR family
Cellular Component: Golgi apparatus; transport vesicle; internal side of plasma membrane; cell surface; membrane; integral to plasma membrane; perinuclear region of cytoplasm; endoplasmic reticulum; lysosome; cytoplasm; integral to membrane; plasma membrane; cytoplasmic vesicle; nucleus
Molecular Function: transferase activity; protein binding; fibroblast growth factor binding; fibroblast growth factor receptor activity; protein-tyrosine kinase activity; transferase activity, transferring phosphorus-containing groups; nucleotide binding; transmembrane receptor protein tyrosine kinase activity; kinase activity; ATP binding; protein kinase activity
Biological Process: peptidyl-tyrosine phosphorylation; apoptosis; somatic stem cell maintenance; protein amino acid autophosphorylation; negative regulation of transcription from RNA polymerase II promoter; protein amino acid phosphorylation; bone mineralization; positive regulation of tyrosine phosphorylation of Stat3 protein; negative regulation of cell proliferation; substantia nigra development; cell-cell signaling; positive regulation of MAPKKK cascade; inner ear receptor cell differentiation; positive regulation of neuron apoptosis; forebrain development; positive regulation of cell proliferation; morphogenesis of an epithelium; response to axon injury; oligodendrocyte development; cell differentiation; skeletal development; inner ear development; negative regulation of epithelial cell proliferation; negative regulation of developmental growth; fibroblast growth factor receptor signaling pathway; myelination in the central nervous system; MAPKKK cascade; positive regulation of phosphoinositide 3-kinase activity; digestive tract morphogenesis; positive regulation of tyrosine phosphorylation of Stat1 protein; positive regulation of peptidyl-tyrosine phosphorylation; positive regulation of protein ubiquitination; cartilage development; negative regulation of smoothened signaling pathway; negative regulation of mitosis; negative regulation of astrocyte differentiation; lens morphogenesis in camera-type eye; positive regulation of endothelial cell proliferation; positive regulation of cell differentiation; phosphorylation
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.